The CPNE3 Knockout Raji Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the Raji B lymphocyte line, designed to eliminate CPNE3 protein expression. This genetically disrupted population enables loss-of-function studies of CPNE3, a calcium-dependent phospholipid-binding protein, without introducing monoclonal bias. The use of a polyclonal knockout pool preserves cellular heterogeneity typical of Raji cultures while providing a robust model for investigating CPNE3-dependent signaling and functional phenotypes.
The Raji cell line, established from a Burkitt’s lymphoma patient, is an Epstein?CBarr virus (EBV)-positive human B lymphocyte model widely employed to dissect B-cell receptor signaling, lymphomagenesis, and immune regulation. Raji cells exhibit constitutive activation of NF-??B and serve as a standard system for evaluating oncogenic pathways in B-cell malignancies. Their well-characterized growth characteristics and responsiveness to extracellular stimuli make them suitable for functional genomics approaches, including CRISPR-mediated gene disruption.
CPNE3 encodes a calcium-dependent phospholipid-binding protein that localizes to the plasma membrane and endosomal compartments, where it participates in membrane trafficking and signal transduction. The protein is activated by calcium influx and epidermal growth factor receptor (EGFR) stimulation, and is post-transcriptionally regulated by microRNAs such as miR-218. Mechanistically, CPNE3 interacts with ERBB2, ezrin, and focal adhesion kinase (FAK), promoting phosphorylation of AKT and ERK, and enhancing NF-??B transcriptional activity. Through its association with the actin cytoskeleton, CPNE3 facilitates dynamic remodeling of focal adhesions, thereby driving cell migration and invasion. The integrated signaling network involving EGFR, PI3K, AKT, ezrin, and FAK positions CPNE3 as a central mediator of pro-metastatic behavior in cancer cells.
In the context of B lymphocytes, CPNE3 activity may influence lymphoma progression by modulating EGFR/AKT/NF-??B pathways that govern survival, proliferation, and adhesion. The knockout of CPNE3 in Raji cells provides a unique platform to decipher how this protein contributes to B-cell lymphoma pathogenesis and to evaluate whether its disruption attenuates invasive potential in a lymphoid malignancy model. Since aberrant EGFR signaling and NF-??B activation are hallmarks of several B-cell lymphomas, this knockout model is particularly relevant for exploring targeted therapeutic strategies.
Researchers can employ these knockout cells for functional investigations such as Western blotting and RT-qPCR to confirm CPNE3 ablation, phospho-AKT/ERK analysis to monitor downstream signaling, and flow cytometry to assess apoptosis or cell cycle changes. Migration and invasion assays, combined with immunofluorescence localization of ezrin and FAK, enable direct examination of CPNE3??s role in cytoskeletal dynamics. Additional applications include drug target validation and screening for compounds that specifically affect CPNE3-dependent pathways. For detailed product information or technical support, please contact Ascent Research.
